LOS ANGELES, CA, Rarity PBC, a Public Benefit Corporation dedicated to expanding the availability of transformative gene therapies for rare diseases, announced the closing of a $4.6M seed financing.
Rarity PBC, a Public Benefit Corporation dedicated to expanding the availability of transformative gene therapies for rare diseases, announced the closing of a $4.6M seed financing led by biotech investor Steve Oliveira, Head of Nemean Asset Management. Proceeds will accelerate development of Rarity's lead program: a one-time autologous hematopoietic stem cell gene therapy for adenosine deaminase severe combined immunodeficiency (ADA-SCID).
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
